Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603